Eyenovia Inc (NASDAQ:EYEN) Director Curt H. Labelle acquired 17,985 shares of the company’s stock in a transaction that occurred on Thursday, July 11th. The shares were acquired at an average price of $2.78 per share, for a total transaction of $49,998.30. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website.

Shares of NASDAQ:EYEN opened at $3.39 on Thursday. The company has a 50 day moving average price of $4.36. Eyenovia Inc has a 52 week low of $2.40 and a 52 week high of $7.03.

Eyenovia (NASDAQ:EYEN) last announced its quarterly earnings results on Tuesday, May 14th. The company reported ($0.50) EPS for the quarter, beating the consensus estimate of ($0.51) by $0.01. Equities research analysts forecast that Eyenovia Inc will post -1.8 EPS for the current fiscal year.

EYEN has been the topic of several analyst reports. Oppenheimer initiated coverage on shares of Kala Pharmaceuticals in a research note on Wednesday, April 24th. They issued an “outperform” rating and a $11.00 price target on the stock. Zacks Investment Research upgraded shares of FirstService from a “strong sell” rating to a “hold” rating and set a $110.00 price target on the stock in a research note on Tuesday, June 25th. Finally, HC Wainwright restated a “buy” rating on shares of Zomedica Pharmaceuticals in a research note on Wednesday, June 5th.

A hedge fund recently bought a new stake in Eyenovia stock. Bank of New York Mellon Corp acquired a new stake in Eyenovia Inc (NASDAQ:EYEN) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 12,529 shares of the company’s stock, valued at approximately $36,000. Bank of New York Mellon Corp owned approximately 0.11% of Eyenovia at the end of the most recent reporting period. Hedge funds and other institutional investors own 10.79% of the company’s stock.

About Eyenovia

Eyenovia, Inc, a clinical stage biopharmaceutical company, engages in developing a pipeline of ophthalmology products in the United States. It is developing MicroProst, which is in Phase III clinical trials for the treatment of chronic angle closure glaucoma; MicroStat, which is in Phase III clinical trials for the treatment of mydriasis; MicroTears for the treatment of dry eye; and MicroPine for the treatment of myopia.

Further Reading: Institutional Investors

Receive News & Ratings for Eyenovia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyenovia and related companies with MarketBeat.com's FREE daily email newsletter.